Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: email@example.com. Type 508 Accommodation and the title of the report in the subject line of e-mail.
FDA Approval of Expanded Age Indication for a Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
On December 4, 2008, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium). Boostrix is now licensed for use in persons aged 10--64 years as a single-dose booster immunization; the vaccine initially was licensed for persons aged 10--18 years. This announcement summarizes the indications for use of Boostrix. Complete recommendations of the Advisory Committee on Immunization Practices (ACIP) for Tdap vaccines have been described previously (1--3).
On October 23, 2008, ACIP was presented data on the safety and immunogenicity of Boostrix in adults aged 19--64 years and notified of the impending expanded age indication for Boostrix. Guidance for the use of Boostrix is the same as for Adacel (Sanofi Pasteur, Toronto, Canada), another Tdap vaccine licensed for use in adults.
Data were reviewed by ACIP from two clinical trials conducted among U.S. adults aged 19--64 years. In both trials, the safety and reactogenicity profiles of Boostrix generally were similar to those of Adacel. For diphtheria and tetanus, immune responses to Boostrix were noninferior. Pertussis antibody concentrations for pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin in the first clinical trial were noninferior to those of infants after a primary diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccination series with Infanrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) in a clinical trial in which efficacy of DTaP also was demonstrated (4--6). Boostrix contains the same three pertussis antigens as Infanrix but in reduced quantities.
Coadministration with influenza vaccine was evaluated in the second trial. In this trial, seroresponse to concomitantly or separately administered Boostrix and influenza vaccine Fluarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) were noninferior for diphtheria, tetanus, PT, and influenza. Noninferiority criteria were marginally exceeded for FHA and pertactin responses; however, serologic correlates of protection for pertussis have not been established. Antibody levels in both groups exceeded those observed in infants after primary DTaP vaccination, in trials in which efficacy of DTaP against pertussis disease was subsequently demonstrated. Decreased immune response to Tdap pertussis antigens when coadministered with influenza vaccine has been reported previously for other U.S.-licensed Tdap vaccines (7).
Indications and Guidance for Use
For prevention of tetanus, diphtheria, and pertussis, adolescents and adults are recommended to receive a one-time booster dose of Tdap. Adolescents aged 11--18 years who have completed the recommended childhood diphtheria and tetanus toxoids and pertussis vaccine (DTP)/DTaP vaccination series should receive a single dose of Tdap instead of tetanus and diphtheria toxoids (Td) vaccine, preferably at a preventive care visit at age 11 or 12 years (1). For adults aged 19--64 years who previously have not received a dose of Tdap, a single dose of Tdap should replace a single decennial Td booster dose (2).
Boostrix is now indicated for use as a single-dose booster immunization in persons aged 10--64 years. The recommended interval between 2 doses of Td-containing vaccines in adolescents and adults is at least 5 years because of concern over increased reactogenicity (1,2); however, data are available suggesting that intervals as short as approximately 2 years are safe (8). An interval <5 years between Td and Tdap may be used if increased risk for acquiring pertussis (e.g., during outbreaks or periods of increased pertussis activity in the community, or among health-care workers) exists (1,2). The safety and effectiveness of Tdap have not been established in pregnant women, nursing mothers, and children aged <10 years. Current doses in stock can be used for persons aged 10--64 years.
- CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-3).
- CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR 2006;55(No. RR-17).
- CDC. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57(No. RR-4).
- Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, March 15, 2005, briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097b1.htm.
- Food and Drug Administration. Product approval information-licensing action. Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at http://www.fda.gov/cber/approvltr/tdapgla050305l.htm.
- Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37--41.
- McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007;25:3464--74.
- Halperin SA, Sweet L, Baxendale D, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J 2006;25:195--200.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.
Date last reviewed: 4/15/2009